Mr. Cameron Groome reports
MICROBIX ANNUAL GENERAL MEETING PROCESS UPDATE
Microbix Biosystems Inc. has provided an update about its annual general meeting (AGM). The AGM will still be held on March 31, 2020, at 1 p.m., however, due to the closure of the company's planned venue and alternative venues, it will be proceeding with access being provided on-line or via teleconference only.
Due to the COVID-19 pandemic, Microbix also wants to avoid the need for in-person attendees at this year's AGM, a goal enabled by setting up an on-line link to allow shareholders to listen to the AGM and view a CEO (chief executive officer) presentation. Microbix will also provide a teleconference number, so that shareholders without up-to-date computer access can listen in by telephone. Details for these modes of remotely attending the AGM will be provided on the company's website
by end of day Friday, March 27, 2020.
It should be noted that there will be no on-line voting at the AGM. Microbix therefore reminds shareholders to vote in advance as outlined in the notice and access letter previously sent. The deadline for voting or receiving proxies in relation to this year's AGM is Friday, March 27, 2020, at 5 p.m. ET. Voting results for the resolutions to be considered by shareholders will be announced by news release following the AGM.
Microbix regrets that shareholders may not attend this year's AGM in person. However, as a virology company, the company is very cognizant of the risks of COVID-19 and wants to help ensure the health and safety of its shareholders and its staff.
Lastly, Microbix's business is considered essential to public health in Canada and internationally, so it intends to remain fully operational during this crisis. In so doing, Microbix has the overwhelming support of its many customers and its staff, for whom measures are being taken to maximize their safety.
About Microbix Biosystems Inc.
Microbix develops proprietary biological and technology solutions for human health and well-being, with sales usually exceeding $1-million per month and approximately 80 skilled employees. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, train lab personnel, or help ensure quality control of clinical diagnostic tests.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.